Internal Medicine Alert – June 30, 2021
June 30, 2021
View Issues
-
Importance of Atherosclerotic Disease Risk Factors in Myocardial Infarction Patients
ST-elevation myocardial infarction patients without standard risk factors recorded a higher all-cause mortality rate that was particularly evident in women. Using proper therapy in these patients may attenuate this risk. -
Another Agent for Hypercholesterolemia
A pooled analysis of three trials of inclisiran in patients with atherosclerotic cardiovascular disease or its risk equivalent showed impressive reductions in LDL cholesterol with subcutaneous injections. -
The Danger of ADHD Overdiagnosis
A growing concern about overdiagnosis of attention-deficit/hyperactivity disorder in adolescents and children demonstrates a need for a decisive answer to this concern. -
Rapid Intermittent Bolus of Hypertonic Saline May Be Better Way to Correct Symptomatic Hyponatremia
Hypertonic saline given via rapid intermittent bolus therapy was as effective and safe as slow continuous infusion, and was associated with a lower rate of recorrecting treatment and higher efficacy in achieving goal sodium within one hour. -
Ischemic Stroke in Patients with COVID-19
Since the first cases of COVID-19 were reported in the United States, severe ischemic strokes also have been reported in some of these patients, some with large vessel occlusions and case reports of thrombectomy for treatment. -
Stroke and Risk of Suicide
Stroke should be considered a risk factor for suicide. Tactics to screen and treat depression and suicidal ideation should be an important component of long-term follow-up and care for stroke patients. -
Pegcetacoplan Injection (Empaveli)
The FDA has approved a new treatment for paroxysmal nocturnal hemoglobinuria, a rare, life-threatening blood disease.